Glycadia, Inc. is a clinical stage biopharmaceutical company developing therapeutics for the prevention and treatment of vascular complications of diabetes.
Glycadia's science is based on recent discoveries concerning the causal role of circulating glycated proteins in the development of complications of diabetes involving the kidney, eye and other organs. The process of nonenzymatic glycation is accelerated in diabetes, giving rise to elevated amounts of glucose-modified proteins that trigger untoward cellular events and promote organ damage. The company's drug development programs are focused on inhibiting the excess nonenzymatic glycation of key proteins to reduce the burden of these blood-borne factors that trigger abnormalities in cell signaling pathways and molecular mediators that underlie diabetic nephropathy, retinopathy, and cardiovascular disease, which continue to occur and progress despite the availability of newer glucose-lowering agents.
Glycadia's core technology was developed by its leading scientists and collaborators at the University of Pennsylvania. The company owns a rich patent estate covering these technologies and its new chemical entities.
The company has raised approximately $25 million from private investors and competitively awarded SBIR grants from the National Institutes of Health.
Glycadia Pharmaceuticals 1880 JFK Blvd, Suite 200 Philadelphia, PA 19103
215.557.8021 · Fax
Developing safe and effective treatments for diabetic complications.™